It was approved by the US Food and Drug Administration (FDA) in November 2021 and the European Medicines Agency (EMA) in February 2019 for adults with PV and is the first and only IFN approved for PV treatment (19, 20). This evidence concerns the gene IFNA1 and acquired polycythemia vera.